Stephen Bardin - 24 Jun 2025 Form 4 Insider Report for CalciMedica, Inc. (CALC)

Role: Chief Financial Officer
Signature: /s/ John Dunn, Attorney-in-Fact
Issuer symbol: CALC
Transactions as of: 24 Jun 2025
Net transactions value: +$3,005
Form type: 4
Filing time: 26 Jun 2025, 18:30:22 UTC
Previous filing: 03 Jun 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bardin Stephen	Chief Financial Officer	C/O CALCIMEDICA, INC., 505 COAST S. BLVD, #307, LA JOLLA	/s/ John Dunn, Attorney-in-Fact	26 Jun 2025	0001942596

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CALC	Common Stock	Purchase	$3,005	+2,000	+200%	$1.50	3,000	26 Jun 2025	See Footnote	F1, F2, F3
holding	CALC	Common Stock						40,000	24 Jun 2025	Direct	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CALC	Employee Stock Option (Right to Buy)	Award	$0	+20,000		$0.000000	20,000	24 Jun 2025	Common Stock	20,000	$1.53	Direct	F5, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The weighted average purchase price for the transaction reported was $1.5025, and the range of prices were between $1.45 and $1.54. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided.
F2	Includes 1,000 shares held by The Bardin Family Trust dated June 4, 2024 (the "Trust") which were inadvertently reported as directly owned on the Form 4 filed with the SEC on June 3, 2025.
F3	By The Bardin Family Trust dated June 4, 2024.
F4	Excludes 1,000 shares held by the Trust which were inadvertently reported as directly owned on the Form 4 filed with the SEC on June 3, 2025.
F5	The option grant was approved by the Board of Directors of CalciMedica, Inc. (the "Company") on April 23, 2025, subject to stockholder approval of an amendment of the Company's 2023 Equity Incentive Plan (the "Amended 2023 EIP") under which the option was granted. The Company's stockholders approved the Amended 2023 EIP on June 24, 2025.
F6	Immediately exercisable.